Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMLVAX100 Vaccine in CML Patients on Imatinib
NCT00466726Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Mar 2007
- Primary completion
- Jul 2014
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CMLVAX100 in chronic myelogenous leukemia (CML), sponsored by GIMEMA. Started Mar 2007; status: completed.
02
Drugs
CMLVAX100
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00466726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00466726.